Design, synthesis and evaluation of some chalcone derivatives as antiproliferative agents
2022
0 views
0 downloads
Advisor: Prof. Dr. Filiz Esra Önen Bayram
Abstract (EN)
KALE, S. Design, Synthesis and Evaluation of some chalcone derivatives as antiproliferative agents, Yeditepe University Institute of Health Science, Thesis on Pharmaceutical Chemistry Master of Science Degree Programme, Istanbul, 2022. Chalcones or 1,3-diaryl-2-propen-1-ones are naturally occuring compounds that belong to the flavonoid family. Chemically, they consist of a three-carbon α,β-unsaturated carbonyl system and two aromatic rings attached to the terminal carbons. In this study, 11 novel benzimidazole chalcone derivatives were synthesized and their structures were elucidated with the help of FT-IR, 1H-NMR, 13C-NMR, LC-MS and elemental analysis. The activities of 11 synthesized compounds against MCF7 breast, HUH7 liver, and HCT116 colon cancer cells were investigated. It was observed that the synthesized compounds 3c, 3e and 3g showed activity against HCT116 colon cancer cells. Keywords: benzimidazole, chalcone, anticancer, NCI-Sulforhodamine assay
Author
Sedat Kale
How to Cite
Sedat Kale (Master Thesis). Design, synthesis and evaluation of some chalcone derivatives as antiproliferative agents, 2022, Yeditepe University.
Keywords
License
Tüm Hakları Saklıdır
This work is shared under the specified license terms.
More theses from Yeditepe University
- Studies on cyclodextrin complexation of a poorly water soluble anti-hyperlipidemic drug, tablet formulation and characterization(2021)
- Washington ambassadors in Turkish-US relations (1927-1960)(2023)
- Metamorphosis of female voices: A study of the violation of women in Greek and Roman mythology and feminist rewritings reclaiming the narrative(2022)
- Knowledge distillation with foundation models for image segmentation(2023)
- The relationship between machiavelism, grandiose and vulnerable narcissism, and loneliness among white collar workers(2023)
- Evaluation of drug-drug interaction checkers along clinically relevant adverse drug events in oncology and hematology pediatric patients(2023)